The company said net income, diluted, for Q1 2025 (3 months) was $42,364 thousand ($0.06 per share), diluted Nareit FFO was $323,279 thousand ($0.45 per share), and diluted FFO as Adjusted was $329,713 thousand ($0.46 per share). Net income for Q1 2024 was $6,477 thousand ($0.01 per share).

1. 01

   The company said net income, diluted, for Q1 2025 (3 months) was $42,364 thousand ($0.06 per share), diluted Nareit FFO was $323,279 thousand ($0.45 per share), and diluted FFO as Adjusted was $329,713 thousand ($0.46 per share). Net income for Q1 2024 was $6,477 thousand ($0.01 per share).

2. 02

   Healthpeak said year-over-year growth in Total Merger-Combined SS Cash (Adjusted) NOI for Q1 2025 over 3 months was 7.0%. By segment, Outpatient Medical was 5.0%, Lab was 7.7%, and CCRC was 15.9%.

3. 03

   The company said it reaffirmed its full-year 2025 guidance ranges. Diluted earnings per common share are expected at $0.30 to $0.36, diluted Nareit FFO and FFO as Adjusted per share at $1.81 to $1.87 each, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth at 3.0% to 4.0%.

4. 04

   The company said it issued $500 million of 5.375% fixed-rate senior unsecured notes due 2035 in February 2025. It said it used the net proceeds to repay a portion of its commercial paper and for general corporate purposes.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.